NEW CFO AT GENSIAGensia Pharmaceuticals (NASDAQ:GNSA), a San Diego developerand manufacturer of novel human pharmaceutical products, hasnamed Daniel D. Burgess chief financial officer, treasurer andsenior director, effective Aug. 1. Burgess, who had beenassociate director and manager of finance, replaces Arthur C.Johnson, who will resign Sept. 30 to open a consulting firm inthe Southeast.
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) has named toits board two scientists who shared the 1985 Nobel Prize:Michael S. Brown, professor of medicine and genetics, andJoseph L. Goldstein, professor for genetic diseases, both of theUniversity of Texas Southwestern Medical Center at Dallas.Regeneron, based in Tarrytown, N.Y., is developing compoundsused to treat neurodegenerative diseases and nerve injuries.Brown and Goldstein are also both members of Regeneron'sscientific advisory board.
Brian H. Dovey, general partner of the venture capital firmDomain Associates, has been named chairman of the board ofdirectors of Athena Neurosciences Inc., a South San Francisco,Calif., focuses on neurological diagnosis and treatmentproducts. Brook H. Byers, of Kleiner Perkins Caufield & Byers,who has served as chairman of the board since 1987, willbecome director of Athena, a position Dovey has occupied since1989.
Nathaniel Berkowitz, managing director, chief executiveofficer and bankruptcy committee member of InFerGene Co.(NASDAQ:IFGN), a San Francisco maker of medical diagnostics,has resigned. Daniel R. Licon, a recently elected member ofInFerGene's board, has been named president and CEO. JamesMcKenzie, who holds 5 percent of InFerGene's stock, has alsobeen named to the board.
Claudio Rocchietta, executive vice president of Novamont, awholly owned subsidiary of Italian agrobusiness and chemicalmarketer Feruzzi/Montedison Group, and Carl V. Stinnett,managing partner of the Market Connection, a Newport Beach,Calif., food company consulting firm, have been named to theboard of directors of Calgene (NASDAQ: CGNE). Calgene ofDavis, Calif., develops and markets improved plant productsand varieties.
William R. Miller, former director and vice chairman of theboard of Bristol-Myers Squibb Co., has been elected to theboard of directors of Glycomed Inc. (NASDAQ:GLYC), a developerof complex carbohydrate pharmaceuticals.
Desmond H. O'Connell, chairman of the board and chiefexecutive officer of Osteotech (NASDAQ:OSTE), a Shrewsbury,N.J., processor and marketer of bone, ligaments and tendons forhuman transplants, has taken an indefinite leave of absence formedical reasons. Patrick A. McBrayer, president and chiefoperating officer, will act as chief executive officer untilO'Connell is able to resume his duties.-- Jeff Hutkoff
(c) 1997 American Health Consultants. All rights reserved.